RCUS Arcus Biosciences: Projected Price to Earnings

RCUS (Arcus Biosciences, Inc.) - company brandmark

Arcus Biosciences, Inc. (RCUS) possesses significant potential to capture oncology market share thanks to support from Gilead. The company's expected P/E ratio aligns with market trends, while 0.00 reflects the current value of this metric. Business growth is based on the results of new molecule tests and patents. High confidence within the scientific community regarding innovative developments strengthens the brand's professional image.

arcusbio.com - RCUS Future Price to Earnings Multiple (period 07/04/2022 - 11/15/2026)

Metric breakdowns and analytics for arcusbio.com (RCUS)

Fundamental company analysis:Arcus Biosciences Inc RCUS
Signature product of Arcus Biosciences, Inc.

The forward P/E compares the current market value of Arcus Biosciences, Inc. (RCUS) with expected earnings, accounting for a premium for potential growth. For an immuno-oncology drug developer, such a valuation based on forward P/E reflects market confidence in the commercial success of its drugs with minimal environmental compliance costs. The current calculated level of 0.00 captures the balance between risks and expectations. The indicator's dynamics help determine the fair value range of the asset, confirming the resilience of the business's fundamental valuations.

Analysis of competing companies

Forward P/E Multiple IBRX|Immunocore Holdings plc (IMCR) - Forward Price to Earnings Multiple|Janux Therapeutics Inc - Projected Price to Earnings|Zymeworks (ZYME) - Projected Price to Earnings Ratio|TNGX: Projected Price to Earnings|Future Price to Earnings Multiple IOVA (Iovance Biotherapeutics, Inc.)|IMTX: Forward P/E Multiple|XNCR - Market Cap to Projected Earnings|Future Price to Earnings compasstherapeutics.com|Projected Price to Earnings replimune.com (REPL)|Future Price to Earnings Lyell (LYEL)|Projected Price to Earnings Innate Pharma, S.A. IPHA|Pyxis Oncology Inc. - Projected Price to Earnings|Forward P/E Multiple Compugen Ltd. CGEN|IOBT - Future Price to Earnings|STRO (sutrobio.com) - Price to Future Earnings Ratio|MiNK Therapeutics, Inc (INKT) - Future Price to Earnings|Projected Price to Earnings Ratio Werewolf Therapeutics (HOWL)|Projected Price to Earnings IMMX|ALXO - Forward Price to Earnings Multiple|Forward P/E Multiple CUE|Market Cap to Future Earnings Ratio PDSB|Forward P/E Multiple SONN (Sonnet BioTherapeutics)|Future Price to Earnings Multiple MAIA|liminatuspharma.com - Forward P/E Multiple|Projected Price to Earnings Ratio LAVA Therapeutics|NextCure, Inc. (NXTC) - Future Price to Earnings|Leap Therapeutics Inc - Future Price to Earnings Multiple|INTS (Intensity Tx) - Forward P/E Multiple|Forward P/E Multiple senseibio.com|Future Price to Earnings Theriva Biologics (TOVX)|GRTS: Price to Expected Earnings Ratio|Forward P/E Multiple KA (kinetabio.com)|neximmune.com (NEXI) - Projected Price to Earnings Ratio|TSBX: Projected Price to Earnings|VCNX: Future Price to Earnings|HARP: Forward P/E Multiple